XTAEARAN
Market cap26mUSD
Dec 25, Last price
2,003.00ILS
1D
-1.33%
1Q
7.40%
Jan 2017
-23.17%
Name
Aran Research and Development 1982 Ltd
Chart & Performance
Profile
Aran Research & Development (1982) Ltd. engages in the product design and development, and equipment manufacturing businesses for plastics industry in Israel. The company develops various medical devices, such as cardiovascular devices, in-vitro diagnostics, surgical instruments, imaging and monitoring devices, and other products; and water devices and fluid management systems, including pressure and flow regulators, electric and hydraulic valves, air release valves, sprinklers, drippers, taps, water meters, filters, check valves, electronic controllers, and testing devices. It also provides portable and stationary control stations for unmanned systems; electro-optics; rugged electronics for ground, marine, and aerial platforms operating in harsh environments; ground systems for access control and security forces; test equipment; production line facilities; measurement and weighing devices; specialty printers; automatic beverage machines; computerized shopping carts and self-checkout kiosk; industrial and communication devices; and batteries. In addition, the company supplies machines and equipment, such as injection molding machines, robotics and automation, injection molds, hot runner systems, drying dosing and conveying systems, plasticizing screws barrels, ultrasonic welding and cleaning, and raw materials; and support services, as well as invests in medical startups. Aran Research & Development (1982) Ltd. was incorporated in 1982 and is based in Caesarea, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 171,948 -1.12% | 173,902 -15.47% | 205,723 114.29% | |||||||
Cost of revenue | 176,026 | 137,693 | 175,367 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (4,078) | 36,209 | 30,356 | |||||||
NOPBT Margin | 20.82% | 14.76% | ||||||||
Operating Taxes | 1,640 | 11,353 | 2,680 | |||||||
Tax Rate | 31.35% | 8.83% | ||||||||
NOPAT | (5,718) | 24,856 | 27,676 | |||||||
Net income | 16,086 -31.54% | 23,496 114.71% | 10,943 263.55% | |||||||
Dividends | (6,000) | (3,000) | (3,000) | |||||||
Dividend yield | 5.68% | 2.46% | 2.62% | |||||||
Proceeds from repurchase of equity | 258 | |||||||||
BB yield | -0.21% | |||||||||
Debt | ||||||||||
Debt current | 38,191 | 28,945 | 28,928 | |||||||
Long-term debt | 43,800 | 85,958 | 65,812 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 4,592 | 3,214 | 4,339 | |||||||
Net debt | 69,021 | 55,886 | 8,518 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 6,156 | (52,372) | (23,880) | |||||||
CAPEX | (7,157) | (2,792) | (1,246) | |||||||
Cash from investing activities | (2,314) | 28,210 | 2,004 | |||||||
Cash from financing activities | (41,660) | (7,896) | 52,221 | |||||||
FCF | (55,138) | (28,787) | 21,933 | |||||||
Balance | ||||||||||
Cash | 12,970 | 48,800 | 76,659 | |||||||
Long term investments | 10,217 | 9,563 | ||||||||
Excess cash | 4,373 | 50,322 | 75,936 | |||||||
Stockholders' equity | 27,406 | 84,467 | 63,402 | |||||||
Invested Capital | 173,632 | 142,338 | 94,668 | |||||||
ROIC | 20.97% | 40.70% | ||||||||
ROCE | 18.79% | 19.20% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 4,886 | 4,886 | 4,886 | |||||||
Price | 21.62 -13.31% | 24.94 6.35% | 23.45 29.84% | |||||||
Market cap | 105,635 -13.31% | 121,857 6.35% | 114,577 29.84% | |||||||
EV | 179,602 | 179,878 | 124,127 | |||||||
EBITDA | 1,358 | 40,679 | 36,640 | |||||||
EV/EBITDA | 132.26 | 4.42 | 3.39 | |||||||
Interest | 1,855 | 2,107 | 837 | |||||||
Interest/NOPBT | 5.82% | 2.76% |